Comparative Pharmacology
Head-to-head clinical analysis: PARCOPA versus STALEVO 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARCOPA versus STALEVO 100.
PARCOPA vs STALEVO 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbidopa inhibits decarboxylation of levodopa in the periphery, increasing levodopa availability to the brain. Levodopa is converted to dopamine in the CNS, replenishing dopamine levels in the striatum.
Stalevo 100 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AAAD), thereby increasing dopamine levels in the brain. Carbidopa inhibits peripheral AAAD, reducing the conversion of levodopa to dopamine outside the brain, which increases the amount of levodopa available for CNS entry and decreases side effects. Entacapone is a reversible inhibitor of catechol-O-methyltransferase (COMT), which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life and duration of action of levodopa.
0.5 mg orally three times daily, titrated slowly based on response and tolerability; maximum 8 mg/day.
One tablet (carbidopa 25 mg / levodopa 100 mg / entacapone 200 mg) orally three to four times daily, maximum 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3 hours; in elderly patients, half-life may be prolonged due to reduced renal clearance, requiring dose adjustment.
Levodopa: 1.5-2 h (peripherally); with carbidopa: prolongs to ~2.5 h. Carbidopa: 2-3 h. Clinical context: requires continuous dopaminergic stimulation to avoid motor fluctuations.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal: ~90% (levodopa metabolites), ~80% (carbidopa unchanged and metabolites); biliary/fecal: minimal
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent